Bruce D. Cheson, MD; Gilles Salles, MD, PhD

Disclosures

June 13, 2013

In This Article

Follicular Lymphoma: Curable or Chronic Disease?

Dr. Cheson: Absolutely. Should we change our goal in follicular lymphoma? We are going to eventually cure this disease. It will be a disease like diabetes or hypertension, where you just take a pill every day for the rest of your life and you feel fine, but you are not really disease-free. Should we change that and abandon the goal of a cure?

Dr. Salles: We should not abandon the goal of a cure. We have made so much progress in recent years with increasing complete remission rates and with new tools to monitor patients, such as MRT and PET/CT, that we improved the complete remission rate, we improved the molecular complete remission rate, and we improved progression-free survival and overall survival. So we should continue to aim for that. However, when patients relapse, maybe that is a goal -- the idea that we can maintain these patients for an extended period of time.

The point of the long-term treatment with this agent is that so far we haven't seen mutants or resistance, but I am convinced they will occur, and that given the biology of B cells that mutate many genes, we will very quickly see the emergence of mutant clones. So, that is an argument for a combination with chemotherapy or a combination with several drugs.

Dr. Cheson: Designing clinical trials with these drugs is a challenge, particularly in combination chemotherapy, because the response rates are so high. Your group has made one of the most important contributions to this field -- the 2 studies[4,5] on PET scans showing that PET scan negativity is potentially a surrogate endpoint. We are using that in our clinical trials now. That is the way to go, and it has been a really great contribution.

Dr. Salles: Thank you for mentioning this work. We looked retrospectively at the patients from the PRIMA study,[4] but also prospectively in another study[5] and identified that in patients receiving rituximab chemotherapy, having a negative PET/CT at the end of the induction was predictive of progression-free survival and overall survival. We need to bring that into our practice.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....